Generic Name: fam-trastuzumab deruxtecan-nxki
Drug Class: Targeted Therapy Medications
Company: Daiichi Sankyo/AstraZeneca
Approval Status: Approved
Generic Version Available: No
Experimental Code: DS-8201
Enhertu is a HER2 antibody combined with a chemotherapy drug. It is approved for previously treated people with inoperable or metastatic HER2-positive breast cancer and for those with people with locally advanced or metastatic HER2-positive gastric (stomach) or gastroesophageal junction cancer.
Human epidermal growth factor receptor 2 (HER2) plays a role in cell division and repair, and blocking these receptors can slow cancer growth. About 20% of breast cancers have a high level of HER2 expression. Enhertu is an antibody-drug conjugate that consists of trastuzumab (Herceptin) plus a topoisomerase inhibitor drug that kills cancer cells.
In the Phase II DESTINY-Breast01 trial, women treated with Enhertu had an overall response rate of 61%. The estimated median progression-free survival (PFS) was 16.4 months. In the DESTINY-Gastric01, the overall response rate was 41% and PFS was 5.6 months in people with gastric or gastroesophageal junction cancer. Enhertu was first approved in 2019.
Enhertu is administered as an intravenous infusion, usually every three weeks until disease progression or unacceptable side effects occur.
Common side effects include nausea, vomiting, fatigue, hair loss, diarrhea constipation, decreased appetite and cough. Enhertu can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to fatigue, infections and easy bleeding. Potential serious adverse events include lung disease and left ventricular dysfunction. Enhertu can cause fetal harm if used during pregnancy.
Patient Assistance Program Info: https://www.enhertu4u.com/hcp.html
Last Reviewed: January 17, 2021